Condition (MeSH)
Tick-Borne Diseases
ClinicalTrials.gov lists 195 trials for Tick-Borne Diseases or a narrower condition beneath it. Pfizer has the most among industry and government lead sponsors, with 27.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
1 more section with rows
18 of the 195 trials are tagged with Tick-Borne Diseases itself; the rest are tagged with a narrower condition beneath it.
When did Tick-Borne Diseases trials start? (29)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
- Other (Unknown)
Top of scale: 16
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 11 |
| 2025 | 13 |
| 2024 | 16 |
| 2023 | 13 |
| 2022 | 13 |
| 2021 | 13 |
| 2020 | 7 |
| 2019 | 13 |
| 2018 | 6 |
| 2017 | 5 |
Showing 10 of 29 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 13 trials starting in 2026 and about 14 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 31 months from start to primary completion across 19 trials still running at the 2026-10-09 snapshot; registered median of 24 months across 85 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Tick-Borne Diseases trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 10 |
| Phase 1/2 | 7 |
| Phase 2 | 22 |
| Phase 2/3 | 5 |
| Phase 3 | 20 |
| Phase 4 | 22 |
| Not applicable | 39 |
| Observational | 69 |
| Unknown | 1 |
How many Tick-Borne Diseases trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 9 |
| Recruiting | 37 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 5 |
| Completed | 90 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Tick-Borne Diseases trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Pfizer | 27 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 16 |
| U.S. Army Medical Research and Development Command | 4 |
| Novartis | 3 |
Interventions as named in the registry (15)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Doxycline | 16 |
| Tick-Borne Encephalitis (TBE) Vaccine (Inactivated) | 13 |
| Ceftriaxone 4g/ 24h | 10 |
| VLA15 | 7 |
| Symptomatic therapy | 3 |
Showing 5 of 15 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Tick-Borne Diseases trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Gastrointestinal symptoms, Photosensitivity | 56 | 1 |
| Appendicitis | 12 | 4 |
| Suicidal ideation | 12 | 2 |
| Type 1 diabetes mellitus | 10 | 2 |
| Depression | 7 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Tick-Borne Diseases? (11)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Tick-borne lymphadenopathy in northeastern France: a human and vector clinical-epidemiological study. | Parasites & vectors | 2025 | Yes |
| Tick-borne diseases under the radar in the North Sea Region. | Ticks and tick-borne diseases | 2023 | Yes |
| Laboratory Methods for Detection of Infectious Agents and Serological Response in Humans With Tick-Borne Infections: A Systematic Review of Evaluations Based on Clinical Patient Samples. | Frontiers in public health | 2021 | Yes |
| Human pathogens associated with the blacklegged tick Ixodes scapularis: a systematic review. | Parasites & vectors | 2016 | Yes |
| How a multidisciplinary 'One Health' approach can combat the tick-borne pathogen threat in Europe. | Future microbiology | 2015 | Yes |
Showing 5 of 11 publications.
Sub-conditions in MeSH (9)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.